首页> 外文会议>World Congress on Heart Failure--Mechanisms and Management >Fast neutron irradiation for prostate cancer
【24h】

Fast neutron irradiation for prostate cancer

机译:前列腺癌的快速中子辐照

获取原文

摘要

The purpose of this study was to summarize the progress made using fast neutron irradiation in the treatment of prostate cancer at Wayne State University between 1991 and the year 2001. The results of three Phase II studies and one Phase HI study involving nearly 700 patients is summarized in this paper. The Phase II studies were dose finding studies looking at doses of 15, 9, 10, and 11 nGy, respectively. The randomized protocol was a study of sequence looking at the results of treating patients with neutron first versus neutron radiation last. The results demonstrated that the best combination of tumor control probabilities and normal tissue complications was found in a mix of approximately 50% neutrons and 50% photons. Thus, the standard doses become 10 nGy and 40 Gy of photons. The randomized trial demonstrated that the sequence has significant importance and the disease-free survival was 93% for patients treated with neutrons first versus 73% for patients treated with neutrons last. There was no difference in the rate of acute or chronic complications. Finally, an analysis was performed demonstrating which patients may best benefit from the use of neutron irradiation. It was shown that patients with one, two, or three adverse risk factors had a significant improvement in disease-free survival when part of the treatment included neutron radiation versus standard photon radiation alone. Neutron radiation can be delivered safely with effort to see that it is superior to that which can be achieved by conformal photon irradiation by itself. Future work will be done to expand the role of neutron radiation in other clinical disease sites.
机译:本研究的目的是总结1991年至2001年期间韦恩州立大学治疗前列腺癌的快速中子辐照的进展。概述了三阶段研究的结果和一期涉及近700名患者的一期高等学校在本文中。 II期研究是剂量寻找研究,分别观察15,9,10和11岁的剂量。随机方案是对序列的序列研究,这些序列持续治疗中子与中子辐射的患者。结果表明,在大约50%中子和50%光子的混合物中发现了肿瘤控制概率和正常组织并发症的最佳组合。因此,标准剂量成为10岁和40微米的光子。随机试验表明,用中子治疗的患者对中子治疗的患者对中子治疗的患者进行了显着的重要性,无疾病存活率为93%。急性或慢性并发症的速率没有差异。最后,进行了分析,证明哪些患者可能因使用中子辐射的使用而受益。结果表明,当部分处理包括中子辐射与标准光子辐射的一部分包括中子辐射时,患有一种,两种或三个不利危险因素的患者在无病的存活中具有显着的改善。中子辐射可以安全地送努力,以便可以看到它优于通过本身通过共形光子辐射来实现的。将来将在未来的工作扩大中子辐射在其他临床疾病部位的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号